Clinical Outcomes of Patients With Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
Durbin, Sienna M.
MetadataShow full item record
CitationDurbin, Sienna M. 2020. Clinical Outcomes of Patients With Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting. Doctoral dissertation, Harvard Medical School.
AbstractPurpose: As indications for immune checkpoint inhibitor (ICI) therapy have increased in recent years, so has the proportion of patients eligible for this type of therapy. However, a lack of data exists about the risks and benefits of ICI therapy in hospitalized patients, who tend to be frailer and sicker than patients enrolled in clinical trials.
Methods: We conducted a retrospective cohort study among hospitalized patients with metastatic solid tumors who received ICI therapy at our institution, a large academic cancer center, over the course of 4 years. We analyzed the characteristics and outcomes of these patients and identified demographic and clinical factors that could be used to predict mortality.
Results: During the 4-year study period, 106 patients were treated with ICI therapy while admitted to the hospital; 66% of them had Eastern Cooperative Oncology Group (ECOG) Performance Status ≥2, which would have prevented them from enrolling in most clinical trials of ICIs. Fifty-two patients died either during admission or within 30 days of discharge; median overall survival was 1.0 month from discharge, and 15% of patients were alive 6 months after discharge. Independent predictors of death following receipt of inpatient ICI included age ≥65 years, having a cancer type other than melanoma, and prior treatment with two or more lines of therapy.
Conclusions: The poor overall outcomes observed in this study may give clinicians pause when considering ICI therapy for hospitalized patients, particularly those with characteristics that are associated with a greater risk of mortality.
Citable link to this pagehttps://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37364992